Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia - PubMed (original) (raw)
Clinical Trial
doi: 10.1038/leu.2009.250. Epub 2009 Dec 17.
M Aricò, G Basso, A Biondi, E Barisone, C Messina, R Parasole, G De Rossi, F Locatelli, A Pession, N Santoro, C Micalizzi, M Citterio, C Rizzari, D Silvestri, R Rondelli, L Lo Nigro, O Ziino, A M Testi, G Masera, M G Valsecchi; Associazione Italiana di Ematologia ed Oncologia Pediatrica
Affiliations
- PMID: 20016536
- DOI: 10.1038/leu.2009.250
Clinical Trial
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia
V Conter et al. Leukemia. 2010 Feb.
Abstract
We analyzed the long-term outcome of 4865 patients treated in Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia (ALL) of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Treatment was characterized by progressive intensification of systemic therapy and reduction of cranial radiotherapy. A progressive improvement of results with reduction of isolated central nervous system relapse rate was obtained. Ten-year event-free survival increased from 53% in Study 82 to 72% in Study 95, whereas survival improved from 64 to 82%. Since 1991, all patients were treated according to Berlin-Frankfurt-Muenster (BFM) ALL treatment strategy. In Study 91, reduced treatment intensity (25%) yielded inferior results, but intensification of maintenance with high-dose (HD)-L-asparaginase (randomized) allowed to compensate for this disadvantage; in high-risk patients (HR, 15%), substitution of intensive polychemotherapy blocks for conventional BFM backbone failed to improve results. A marked improvement of results was obtained in HR patients when conventional BFM therapy was intensified with three polychemotherapy blocks and double delayed intensification (Study 95). The introduction of minimal residual disease monitoring and evaluation of common randomized questions by AIEOP and BFM groups in the protocol AIEOP-BFM-ALL 2000 are expected to further ameliorate treatment of children with ALL.
Similar articles
- Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G. Conter V, et al. Haematologica. 1998 Sep;83(9):791-9. Haematologica. 1998. PMID: 9825576 Clinical Trial. - Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V. Aricò M, et al. J Clin Oncol. 2008 Jan 10;26(2):283-9. doi: 10.1200/JCO.2007.12.3927. J Clin Oncol. 2008. PMID: 18182669 Clinical Trial. - Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A, Rondelli R, De Rossi G, Lo Nigro L, Porta F, Santoro N, Indolfi P, Basso G, Conter V, Aricò M; Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Paolucci G, et al. Haematologica. 2001 May;86(5):478-84. Haematologica. 2001. PMID: 11410410 Clinical Trial. - More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.
Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. Sallan SE, et al. Haematol Blood Transfus. 1990;33:459-66. doi: 10.1007/978-3-642-74643-7_83. Haematol Blood Transfus. 1990. PMID: 2182437 Review. - Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects.
Chessells JM. Chessells JM. Blood Rev. 1992 Dec;6(4):193-203. doi: 10.1016/0268-960x(92)90015-i. Blood Rev. 1992. PMID: 1486288 Review.
Cited by
- Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Jiménez-Hernández E, Jaimes-Reyes EZ, Arellano-Galindo J, García-Jiménez X, Tiznado-García HM, Dueñas-González MT, Martínez Villegas O, Sánchez-Jara B, Bekker-Méndez VC, Ortíz-Torres MG, Ortíz-Fernández A, Marín-Palomares T, Mejía-Aranguré JM. Jiménez-Hernández E, et al. Biomed Res Int. 2015;2015:576950. doi: 10.1155/2015/576950. Epub 2015 Mar 26. Biomed Res Int. 2015. PMID: 25922837 Free PMC article. - Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui CH, Mullighan CG, Evans WE, Relling MV. Pui CH, et al. Blood. 2012 Aug 9;120(6):1165-74. doi: 10.1182/blood-2012-05-378943. Epub 2012 Jun 22. Blood. 2012. PMID: 22730540 Free PMC article. Review. - Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Baumeister S, Verneris MR, Myers GD, Karras NA, Cooper S, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Fabrizio V, Chinnabhandar V, Kunicki M, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Barsan V, et al. EClinicalMedicine. 2023 Oct 26;65:102268. doi: 10.1016/j.eclinm.2023.102268. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37954907 Free PMC article. - Effect of Testicular Boost in Children With Leukemia Receiving Total Body Irradiation and Stem Cell Transplant: A Single-Institution Experience.
Blomain ES, Jiang A, Donaldson SS, Agarwal R, Bertaina A, Shyr D, Eisenberg ML, Hoppe RT, Hiniker SM, Oh J. Blomain ES, et al. Adv Radiat Oncol. 2022 Sep 13;8(1):101071. doi: 10.1016/j.adro.2022.101071. eCollection 2023 Jan-Feb. Adv Radiat Oncol. 2022. PMID: 36483061 Free PMC article. - Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD. Lipshultz SE, et al. Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. Epub 2010 Sep 16. Lancet Oncol. 2010. PMID: 20850381 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources